Mesa Laboratories Inc. (MLAB) - 10-K Summary
Business Context and Reporting Period
Company: Mesa Laboratories, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: March 31, 2009
Business Overview: Mesa designs, manufactures, and markets instruments and disposable products for industrial and healthcare applications. Key product lines include DATATRACE data loggers, RAVEN biological indicators, medical hemodialysis products (Dialysate Meters), and NUSONICS fluid measurement systems. The company operates facilities in Lakewood, Colorado, and Omaha, Nebraska.
Key Financial Metrics (Fiscal Year 2009)
| Metric | 2009 (in thousands) | 2008 (in thousands) |
|---|---|---|
| Net Sales | $21,536 | $19,558 |
| Gross Profit | $13,817 | $12,858 |
| Gross Margin | 64% | 66% |
| Operating Income | $7,608 | $7,061 |
| Net Income | $4,790 | $4,610 |
| Diluted EPS | $1.48 | $1.41 |
| Cash and Cash Equivalents | $9,111 | $5,770 |
| Working Capital | $17,109 | $12,824 |
| Current Ratio | 13:1 | 9:1 |
| Total Debt | $0 | $0 |
Note: The company maintains no long-term debt or lines of credit.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10% ($1.98 million) compared to fiscal 2008. Growth was driven by a 16% increase in Medical products and a 15% increase in RAVEN biological indicators. DATATRACE sales remained flat due to economic downturns delaying industrial capital purchases, while NUSONICS sales grew slightly (3%) but remain less than 4% of total revenue.
- Profitability: Net income grew 4% to $4.79 million, lagging behind revenue growth. Gross margin decreased from 66% to 64% due to a shift in product mix toward lower-margin RAVEN products and increased cost of sales.
- Liquidity: Cash and cash equivalents increased significantly from $5.77 million to $9.11 million. Net cash provided by operating activities was $5.08 million.
- Efficiency: Days Sales Outstanding (DSO) increased from 60 to 74 days, attributed to longer payment times from foreign customers.
Guidance, Outlook, and Risks
Management Commentary: Management anticipates improving trends in new product shipments and service sales for fiscal 2010, particularly with the introduction of the Micropack RF products for real-time reporting. The company continues to focus on cost reduction programs and price increases to offset rising costs.
Capital Allocation: The company paid quarterly dividends totaling $0.40 per share in 2009. It maintains a share repurchase plan (up to 300,000 shares) and repurchased 1,662 shares in Q4 2009. Capital expenditures were $676,000, largely for automation equipment for RAVEN products.
Risks and Contingencies:
- Customer Concentration: One customer represented approximately 14% of revenues and 12% of accounts receivable in 2009.
- Competition: Intense competition from larger companies with greater resources in medical, data logging, and fluid measurement markets.
- Regulatory: Products are subject to FDA regulations; failure to comply could result in fines or suspension of sales.
- Economic Sensitivity: Industrial customers may delay capital equipment purchases during economic downturns.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the single customer representing 14% of revenue.
- Days Sales Outstanding: Investigate the cause of the DSO increase to 74 days and potential impact on future cash flow.
- Product Mix Shift: Assess the long-term impact of shifting sales toward lower-margin RAVEN products on overall profitability.
- Debt-Free Status: Confirm the company's strategy to remain debt-free while funding acquisitions and R&D.
- Regulatory Compliance: Review any recent FDA inspection reports or regulatory actions affecting medical device lines.